In this study, we founded that activated CD8+ T cell, activated CD4+ T cell, as well as activated B cell were highly infiltrated in the CRC samples with low PRS, indicating PRS might be used to predict the response of CRC to immunotherapies. The gene discussed is CD4; the disease is colorectal carcinoma.